Andrea Mohn-Staudner

Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study

Marina Chiara Garassino, Byoung Chul Cho, Joo-Hang Kim et al. · The Lancet Oncology · 2018 · 568 citations · Full text

Medicine, Immunology, Pathology +5

Prevention, Diagnosis, Therapy, and Follow-up of Lung Cancer

G. Goeckenjan, H. Sitter, Michael Thomas et al. · Pneumologie · 2010 · 150 citations · Full text

Advanced Lung Disease, Interdisciplinary Guideline, Clinical Specialties +25

Association of microsomal epoxide hydrolase polymorphisms and lung cancer risk

Andrea Gsur, Thomas Zidek, K Schnattinger et al. · British Journal of Cancer · 2003 · 79 citations · Full text

Cervical Ultrasound (US) and US-guided Lymph Node Biopsy as a Routine Procedure for Staging of Lung Cancer

Helmut Prosch, Gerhard F. Strasser, C Sonka et al. · Ultraschall in der Medizin - European Journal of Ultrasound · 2007 · 56 citations

Medical Ultrasound, Engineering, Pathology +18

Vinorelbine—gemcitabine in advanced non-small-cell lung cancer (NSCLC): An AASLC phase II trial

G. Krajnik, Andrea Mohn-Staudner, J. Thaler et al. · Annals of Oncology · 2000 · 43 citations · Full text

Oncology, Medicine, Pharmacotherapy +5